Maintenance tobramycin primarily affects untargeted bacteria in the CF sputum microbiome.

ABSTRACT:

Rationale

The most common antibiotic used to treat people with cystic fibrosis (PWCF) is inhaled tobramycin, administered as maintenance therapy for chronic Pseudomonas aeruginosa lung infections. While the effects of inhaled tobramycin on P. aeruginosa abundance and lung function diminish with continued therapy, this maintenance treatment is known to improve long-term outcomes, underscoring how little is known about why antibiotics work in CF infections, what their effects are on complex CF sputum microbiomes and how to improve these treatments.

Objectives

To rigorously define the effect of maintenance tobramycin on CF sputum microbiome characteristics.

Methods and measurements

We collected sputum from 30 PWCF at standardised times before, during and af

SUBMITTER: Nelson MT 

PROVIDER: S-EPMC7875198 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature